Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
Breaking down fourth quarter of 2022 numbers, the company's experienced
company delivered fourth quarter of 2022 operating loss of $-52.887 million
Published Mar 22 2023
CSIMarket Team / CSIMarket.com
Revenue surged by 73.723 % from $0.14 million in the preceding financial reporting period, grew loss from $-1.49 per share.
For the most recent fiscal period Bioxcel Therapeutics Inc realized net loss of $-54.810 million, higher than $-28.183 million a year ago.
BTAI announced loss of $-165.76 million and revenue of $0.38 million in the fiscal 12 Months 2022.
Net loss per share has widen to $-5.92 from $-4.05 in the prior fiscal year, while by 0 % from $0.00 million a year ago.
Bioxcel Therapeutics Inc is expected to report next financial earnings on May 08, 2023.
Other BTAI's news
BioXcel Therapeutics Grapples with Roadblocks as Plans for Public Offering are Scrapped
Bioxcel Therapeutics Inc: Surging Revenue Brings Growth But Fails to Yield Profitability
Bioxcel Therapeutics Inc Generates Impressive $0.206 Million in Revenue, on Track for Strong 2023
Breaking down fourth quarter of 2022 numbers, the company*s experienced
released Revenue of $0.137 million, in the Sep 30 2022 report
Other BTAI's news
BioXcel Therapeutics Grapples with Roadblocks as Plans for Public Offering are Scrapped
Bioxcel Therapeutics Inc: Surging Revenue Brings Growth But Fails to Yield Profitability
Bioxcel Therapeutics Inc Generates Impressive $0.206 Million in Revenue, on Track for Strong 2023
Breaking down fourth quarter of 2022 numbers, the company*s experienced
released Revenue of $0.137 million, in the Sep 30 2022 report